The company delivered strong Q4 2025 results beating EPS and revenue estimates, demonstrating improved operating income and margins that support investor confidence in organic demand recovery and pricing leverage. FY-2026 guidance of $305M-$325M revenue is near consensus expectations at the midpoint.
Cyborg Score Rationale
NPK International demonstrates solid execution with Q4 beats, strong 14% net margins, and improving returns. However, a 32x P/E ratio suggests elevated valuation risk, and analyst consensus shows mixed conviction ("Moderate Buy") with execution risk in 2026 guidance.
Top Insights
Q4 2025 quarterly revenue of $75.20M exceeded analyst estimates of $69.02M by 9%.
Institutional investors own 80.81% of company stock, indicating strong institutional backing.
Debt-to-equity ratio of 0.03 demonstrates exceptional balance sheet strength.
Stock has "Moderate Buy" consensus rating with average price target of $14.17 from three buy and one hold rating.
Named Competitors
General Chemical Distribution — Larger integrated chemical distributor with broader product portfolio
Life Sciences Distribution — Specialty materials distributor serving pharma and biotech
Industrial Distribution — Broad-based industrial and electrical distributor
Recent Developments
(Feb 2026) Q4 2025 earnings beat: $0.13 EPS vs. $0.11 expected, $75.2M revenue vs. $69.0M consensus
(Feb 2026) Stock reached 52-week high of $15.73 following earnings report
(Nov 2025) HC Wainwright raised price target from $12.00 to $18.00 with buy rating
Open the full interactive NPK International Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.